BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38007758)

  • 1. Therapeutic Efficacy of Oxaliplatin and Pembrolizumab Combination Treatment for Triple-Negative Breast Cancer.
    Chu SL
    Stud Health Technol Inform; 2023 Nov; 308():341-350. PubMed ID: 38007758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin and Checkpoint Inhibitor Induces Immunogenic Cells Death and Promotes Therapeutic Efficacy in the Model of Murine Triple Positive Breast Cancer.
    Shi H
    Stud Health Technol Inform; 2023 Nov; 308():329-340. PubMed ID: 38007757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
    Andreidesz K; Koszegi B; Kovacs D; Bagone Vantus V; Gallyas F; Kovacs K
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
    Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
    Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model.
    Tseng LM; Lau KY; Chen JL; Chu PY; Huang TT; Lee CH; Wang WL; Chang YY; Huang CT; Huang CC; Chao TC; Tsai YF; Lai JI; Dai MS; Liu CY
    Exp Cell Res; 2023 Aug; 429(1):113652. PubMed ID: 37209991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
    Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
    Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of PC4 increases chemosensitivity of Oxaliplatin in triple negative breast cancer by suppressing mTOR pathway.
    Wang Q; Ma L; Chen L; Chen H; Luo M; Yang W; Liao F; Gong Q; Wang Y; Yang Z; Wu J; Zhang C; Zheng J; Han S; Leng Y; Luo P; Shi C
    Biochem Biophys Res Commun; 2021 Mar; 544():65-72. PubMed ID: 33524870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
    Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
    Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
    BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
    Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
    BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
    Chun B; Pucilowska J; Chang S; Kim I; Nikitin B; Koguchi Y; Redmond WL; Bernard B; Rajamanickam V; Polaske N; Fields PA; Conrad V; Schmidt M; Urba WJ; Conlin AK; McArthur HL; Page DB
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
    Wang Z; Cordova LE; Chalasani P; Lu J
    Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
    Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.